Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease

In the acute myeloid leukemia (AML) setting, research has extensively investigated the existence and relevance of molecular biomarkers, in order to better tailor therapy with newly developed agents and hence improve outcomes and/or save the patient from poorly effective therapies. In particular, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Maurillo, Luca, Bassan, Renato, Cascavilla, Nicola, Ciceri, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826465/
https://www.ncbi.nlm.nih.gov/pubmed/31548502
http://dx.doi.org/10.3390/cancers11101417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826465/
https://www.ncbi.nlm.nih.gov/pubmed/31548502
http://dx.doi.org/10.3390/cancers11101417

Ejemplares similares